Table 2

 Baseline characteristics of each non-invasive ventilation (NIV) indication group

COPDCPE + COPDPneumonia + COPDHypercapnic pneumonia +COPDOb-hypoven
CPEtotalHypercapnicNon-hypercapnicPneumoniatotalHypercapnicNon-hypercapnic
APACHE, Acute Physiology and Chronic Health Evaluation; CPE, cardiogenic pulmonary oedema; COPD, chronic obstructive pulmonary disease; F/M, female/male; ob-hypoven, obesity-hypoventilation decompensation.
*Trials with available arterial blood gas data: CPE 63/70; pneumonia 23/27; pneumonia + COPD 20/21.
†Mean ± standard deviation.
‡Median, interquartile range (available data/number trials).
Number trials (number patients)70* (69)45 (44)18 (18)27* (26)12 (12)11 (11)39 (37)1121* (20)18 (17)6 (6)
Age†76.4±12.577.3±1276±10.764.9±14.966±13.762.3±16.871.3±8.183.8±6.474.6±9.973.9±10.158.1±5.4
F/M44/2530/1410/810/164/85/615/227/47/136/113/3
APACHE II†18.3±5.8 (66/70)18.5±5 (45/45)18.7±6.9 (16/18)18.6±5.1 (27/27)20.8±4.4 (12/12)17.7±5.4 (11/11)19±5.3 (38/39)19.4±6.5 (11/11)20.9±4.5 (21/21)21.1±4.8 (18/18)13.5±5.8 (6/6)
pH‡7.277.247.347.377.317.447.267.247.297.277.26
7.19–7.317.16–7.297.29–7.417.3–7.427.16–7.367.39–7.477.21–7.37.19–7.287.22–7.347.21–7.337.22–7.3
(63/70)(45/45)(18/18)(23/27)(12/12)(11/11)(38/39)(11/11)(20/21)(18/18)(6/6)
PaCO2515537.24559.53775.6777172.570.9
42.6–61.149–6730.5–40.737.6–59.553.7–6534.1–4170.8–86.365–78.560.7–9364.7–9768.4–72.7
(63/70)(45/45)(18/18)(23/27)(12/12)(11/11)(39/39)(11/11)(20/21)(18/18)(6/6)
PaO2565662.55449.560616552.150.364.5
46–71.244.7–65.847.2–74.447.6–6347–54.252.1–6747–7343.7–77.546–72.539.5–6955.5–72.9
(62/70)(44/45)(18/18)(23/27)(12/12)(11/11)(37/39)(11/11)(20/21)(18/18)(6/6)
PaO2/FiO2185165.5223142175.5105.5184191161197.5252
134–242.2129–231.5204.2–24491.5–196.7111.7–237.786–173154.5–213.5116.5–257.2144–240146.2–243.7218.5–295
(32/70)(24/45)(9/18)(12/27)(6/12)(6/11)(15/39)(6/11)(9/21)(8/18)(3/6)